首站-论文投稿智能助手
典型文献
NAFLD or MAFLD:That is the conundrum
文献摘要:
Where do we stand and where are we going?This ques-tion is of paramount importance in the light of the necessity of shedding light on the novel,controversial issue that is chang-ing the acronym of nonalcoholic fatty liver disease(NAFLD)to metabolic dysfunction-associated fatty liver disease(MAFLD).
文献关键词:
作者姓名:
Giovanni Tarantino
作者机构:
Department of Clinical Medicine and Surgery,Federico Ⅱ University Medical School of Naples,Naples,Italy
引用格式:
[1]Giovanni Tarantino-.NAFLD or MAFLD:That is the conundrum)[J].国际肝胆胰疾病杂志(英文版),2022(02):103-105
A类:
acronym
B类:
NAFLD,MAFLD,That,conundrum,Where,do,we,stand,where,are,going,This,ques,paramount,importance,light,necessity,shedding,novel,controversial,issue,that,chang,nonalcoholic,fatty,liver,disease,metabolic,dysfunction,associated
AB值:
0.639726
相似文献
Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD:A promising drug Potentilla discolor Bunge
Longshan Ji;Qian Li;Yong He;Xin Zhang;Zhenhua Zhou;Yating Gao;Miao Fang;Zhuo Yu;Robim M.Rodrigues;Yueqiu Gao;Man Li-Laboratory of Cellular Immunity,Institute of Clinical Immunology,Shanghai Key Laboratory of Traditional Chinese Medicine,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Key Laboratory of Liver and Kidney Diseases(Shanghai University of Traditional Chinese Medicine),Ministry of Education,Shanghai 201203,China;Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Department of Hepatopathy,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Department of in Vitro Toxicology and Dermato-Cosmetology,Faculty of Medicine and Pharmacy,Vrije Universiteit Brussel,Brussels 1000,Belgium
Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease
Jie Tong;Dongjie Li;Hongbo Meng;Diyang Sun;Xiuting Lan;Min Ni;Jiawei Ma;Feiyan Zeng;Sijia Sun;Jiangtao Fu;Guoqiang Li;Qingxin Ji;Guoyan Zhang;Qirui Shen;Yuanyuan Wang;Jiahui Zhu;Yi Zhao;Xujie Wang;Yi Liu;Shenxi Ouyang;Chunquan Sheng;Fuming Shen;Pei Wang-Department of Pharmacy,Shanghai Tenth People's Hospital,Tongji University School of Medicine,Shanghai 200072,China;Institute of Nuclear Medicine,Tongji University School of Medicine,Shanghai 200072,China;Department of General Surgery,Shanghai Tenth People's Hospital,Tongji University School of Medicine,Shanghai 200072,China;Department of Pharmacology,School of Pharmacy,Naval Medical University/Second Military Medical University,Shanghai 200433,China;Department of Pharmacy,Shanghai Fourth People's Hospital,Tongji University School of Medicine,Shanghai 200081,China;Shanghai Key Laboratory of Regulatory Biology,Institute of Biomedical Sciences and School of Life Sciences,East China Normal University,Shanghai 200241,China;Chemical Biology Research Center School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou 325000,China;Department of Medicinal Chemistry,School of Pharmacy,Naval Medical University/Second Military Medical University,Shanghai 200433,China
New definition of metabolic dysfunction-associated fatty liver disease with elevated brachial-ankle pulse wave velocity and albuminuria:a prospective cohort study
Jialu Wang;Shanshan Liu;Qiuyu Cao;Shujing Wu;Jingya Niu;Ruizhi Zheng;Lizhan Bie;Zhuojun Xin;Yuanyue Zhu;Shuangyuan Wang;Hong Lin;Tiange Wang;Min Xu;Jieli Lu;Yuhong Chen;Yiping Xu;Weiqing Wang;Guang Ning;Yu Xu;Mian Li;Yufang Bi;Zhiyun Zhao-Department of Endocrine and Metabolic Diseases,Shanghai Institute of Endocrine and Metabolic Diseases,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Shanghai National Clinical Research Center for Metabolic Diseases,Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China,Shanghai Key Laboratory for Endocrine Tumor,State Key Laboratory of Medical Genomics,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Clinical Trials Center,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway
Yi-kuan Wu;Zheng-nan Ren;Sheng-long Zhu;Yun-zhou Wu;Gang Wang;Hao Zhang;Wei Chen;Zhao He;Xian-long Ye;Qi-xiao Zhai-State Key Laboratory of Food Science and Technology,Jiangnan University,Wuxi 214122,China;School of Food Science and Technology,Jiangnan University,Wuxi 214122,China;School of Medicine,Jiangnan University,Wuxi 214122,China;College of Life Science,Northeast Agricultural University,Harbin 150038,China;National Engineering Research Center for Functional Food,Jiangnan University,Wuxi 214122,China;Shandong Key Laboratory of Endocrinology and Lipid Metabolism,Jinan 250021,China;School of Medicine,Shandong University,Jinan 250012,China;Ganjiang Chinese Medicine Innovation Center,Nanchang 330000,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。